![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: FYN |
Gene summary for FYN |
![]() |
Gene information | Species | Human | Gene symbol | FYN | Gene ID | 2534 |
Gene name | FYN proto-oncogene, Src family tyrosine kinase | |
Gene Alias | SLK | |
Cytomap | 6q21 | |
Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | P06241 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2534 | FYN | LZE7T | Human | Esophagus | ESCC | 4.17e-08 | 5.18e-01 | 0.0667 |
2534 | FYN | LZE24T | Human | Esophagus | ESCC | 1.68e-05 | 6.07e-02 | 0.0596 |
2534 | FYN | LZE6T | Human | Esophagus | ESCC | 8.08e-03 | 3.09e-01 | 0.0845 |
2534 | FYN | P2T-E | Human | Esophagus | ESCC | 1.43e-05 | 8.22e-02 | 0.1177 |
2534 | FYN | P4T-E | Human | Esophagus | ESCC | 3.14e-08 | 1.57e-01 | 0.1323 |
2534 | FYN | P5T-E | Human | Esophagus | ESCC | 7.31e-06 | 7.12e-02 | 0.1327 |
2534 | FYN | P9T-E | Human | Esophagus | ESCC | 4.88e-03 | 9.66e-02 | 0.1131 |
2534 | FYN | P10T-E | Human | Esophagus | ESCC | 7.67e-23 | 3.48e-01 | 0.116 |
2534 | FYN | P12T-E | Human | Esophagus | ESCC | 3.69e-19 | 2.47e-01 | 0.1122 |
2534 | FYN | P16T-E | Human | Esophagus | ESCC | 1.11e-13 | 1.99e-01 | 0.1153 |
2534 | FYN | P23T-E | Human | Esophagus | ESCC | 9.15e-04 | 9.56e-02 | 0.108 |
2534 | FYN | P24T-E | Human | Esophagus | ESCC | 1.92e-02 | 3.62e-02 | 0.1287 |
2534 | FYN | P26T-E | Human | Esophagus | ESCC | 1.47e-08 | 4.68e-02 | 0.1276 |
2534 | FYN | P27T-E | Human | Esophagus | ESCC | 8.58e-04 | 1.44e-02 | 0.1055 |
2534 | FYN | P28T-E | Human | Esophagus | ESCC | 3.70e-12 | 2.32e-01 | 0.1149 |
2534 | FYN | P31T-E | Human | Esophagus | ESCC | 8.53e-03 | 4.68e-03 | 0.1251 |
2534 | FYN | P32T-E | Human | Esophagus | ESCC | 1.30e-09 | 8.52e-02 | 0.1666 |
2534 | FYN | P37T-E | Human | Esophagus | ESCC | 3.88e-02 | 1.04e-01 | 0.1371 |
2534 | FYN | P42T-E | Human | Esophagus | ESCC | 6.10e-03 | 4.57e-02 | 0.1175 |
2534 | FYN | P44T-E | Human | Esophagus | ESCC | 4.68e-04 | 1.19e-01 | 0.1096 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003134610 | Oral cavity | OSCC | positive regulation of cell projection organization | 176/7305 | 353/18723 | 1.94e-05 | 1.87e-04 | 176 |
GO:000941018 | Oral cavity | OSCC | response to xenobiotic stimulus | 222/7305 | 462/18723 | 4.00e-05 | 3.48e-04 | 222 |
GO:004352310 | Oral cavity | OSCC | regulation of neuron apoptotic process | 111/7305 | 212/18723 | 5.12e-05 | 4.27e-04 | 111 |
GO:007259316 | Oral cavity | OSCC | reactive oxygen species metabolic process | 122/7305 | 239/18723 | 9.73e-05 | 7.34e-04 | 122 |
GO:00011019 | Oral cavity | OSCC | response to acid chemical | 74/7305 | 135/18723 | 1.38e-04 | 9.76e-04 | 74 |
GO:005086315 | Oral cavity | OSCC | regulation of T cell activation | 161/7305 | 329/18723 | 1.44e-04 | 1.02e-03 | 161 |
GO:00321037 | Oral cavity | OSCC | positive regulation of response to external stimulus | 203/7305 | 427/18723 | 1.79e-04 | 1.22e-03 | 203 |
GO:00508527 | Oral cavity | OSCC | T cell receptor signaling pathway | 68/7305 | 123/18723 | 1.80e-04 | 1.22e-03 | 68 |
GO:009730519 | Oral cavity | OSCC | response to alcohol | 127/7305 | 253/18723 | 1.81e-04 | 1.24e-03 | 127 |
GO:001097510 | Oral cavity | OSCC | regulation of neuron projection development | 210/7305 | 445/18723 | 2.35e-04 | 1.52e-03 | 210 |
GO:000715916 | Oral cavity | OSCC | leukocyte cell-cell adhesion | 178/7305 | 371/18723 | 2.44e-04 | 1.57e-03 | 178 |
GO:00432006 | Oral cavity | OSCC | response to amino acid | 64/7305 | 116/18723 | 2.96e-04 | 1.86e-03 | 64 |
GO:190303715 | Oral cavity | OSCC | regulation of leukocyte cell-cell adhesion | 162/7305 | 336/18723 | 3.39e-04 | 2.08e-03 | 162 |
GO:00182123 | Oral cavity | OSCC | peptidyl-tyrosine modification | 180/7305 | 378/18723 | 3.63e-04 | 2.22e-03 | 180 |
GO:000268310 | Oral cavity | OSCC | negative regulation of immune system process | 204/7305 | 434/18723 | 3.72e-04 | 2.27e-03 | 204 |
GO:005090010 | Oral cavity | OSCC | leukocyte migration | 176/7305 | 369/18723 | 3.80e-04 | 2.31e-03 | 176 |
GO:00712304 | Oral cavity | OSCC | cellular response to amino acid stimulus | 42/7305 | 71/18723 | 4.59e-04 | 2.76e-03 | 42 |
GO:00712295 | Oral cavity | OSCC | cellular response to acid chemical | 46/7305 | 80/18723 | 6.08e-04 | 3.44e-03 | 46 |
GO:0050730 | Oral cavity | OSCC | regulation of peptidyl-tyrosine phosphorylation | 129/7305 | 264/18723 | 6.70e-04 | 3.75e-03 | 129 |
GO:00181083 | Oral cavity | OSCC | peptidyl-tyrosine phosphorylation | 177/7305 | 375/18723 | 6.86e-04 | 3.83e-03 | 177 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05020210 | Esophagus | ESCC | Prion disease | 193/4205 | 273/8465 | 6.42e-13 | 1.34e-11 | 6.89e-12 | 193 |
hsa05130211 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa0452030 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
hsa0407116 | Esophagus | ESCC | Sphingolipid signaling pathway | 85/4205 | 121/8465 | 3.04e-06 | 1.73e-05 | 8.84e-06 | 85 |
hsa0451020 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
hsa0541630 | Esophagus | ESCC | Viral myocarditis | 41/4205 | 60/8465 | 2.59e-03 | 7.05e-03 | 3.61e-03 | 41 |
hsa0436016 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa046607 | Esophagus | ESCC | T cell receptor signaling pathway | 63/4205 | 104/8465 | 1.60e-02 | 3.60e-02 | 1.84e-02 | 63 |
hsa0502038 | Esophagus | ESCC | Prion disease | 193/4205 | 273/8465 | 6.42e-13 | 1.34e-11 | 6.89e-12 | 193 |
hsa05130310 | Esophagus | ESCC | Pathogenic Escherichia coli infection | 142/4205 | 197/8465 | 8.21e-11 | 1.06e-09 | 5.42e-10 | 142 |
hsa04520114 | Esophagus | ESCC | Adherens junction | 69/4205 | 93/8465 | 1.08e-06 | 6.83e-06 | 3.50e-06 | 69 |
hsa0407117 | Esophagus | ESCC | Sphingolipid signaling pathway | 85/4205 | 121/8465 | 3.04e-06 | 1.73e-05 | 8.84e-06 | 85 |
hsa04510111 | Esophagus | ESCC | Focal adhesion | 127/4205 | 203/8465 | 1.25e-04 | 4.99e-04 | 2.56e-04 | 127 |
hsa05416114 | Esophagus | ESCC | Viral myocarditis | 41/4205 | 60/8465 | 2.59e-03 | 7.05e-03 | 3.61e-03 | 41 |
hsa0436017 | Esophagus | ESCC | Axon guidance | 108/4205 | 182/8465 | 5.13e-03 | 1.30e-02 | 6.67e-03 | 108 |
hsa0466013 | Esophagus | ESCC | T cell receptor signaling pathway | 63/4205 | 104/8465 | 1.60e-02 | 3.60e-02 | 1.84e-02 | 63 |
hsa0452016 | Lung | IAC | Adherens junction | 37/1053 | 93/8465 | 1.99e-11 | 2.16e-09 | 1.43e-09 | 37 |
hsa045108 | Lung | IAC | Focal adhesion | 59/1053 | 203/8465 | 1.31e-10 | 1.06e-08 | 7.06e-09 | 59 |
hsa0513016 | Lung | IAC | Pathogenic Escherichia coli infection | 45/1053 | 197/8465 | 2.93e-05 | 6.14e-04 | 4.08e-04 | 45 |
hsa040719 | Lung | IAC | Sphingolipid signaling pathway | 28/1053 | 121/8465 | 7.30e-04 | 6.08e-03 | 4.04e-03 | 28 |
Page: 1 2 3 4 5 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
FYN | SNV | Missense_Mutation | rs376211530 | c.163G>A | p.Ala55Thr | p.A55T | P06241 | protein_coding | tolerated(0.88) | benign(0) | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
FYN | SNV | Missense_Mutation | rs376211530 | c.163N>A | p.Ala55Thr | p.A55T | P06241 | protein_coding | tolerated(0.88) | benign(0) | TCGA-AC-A3EH-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
FYN | SNV | Missense_Mutation | c.925N>A | p.Glu309Lys | p.E309K | P06241 | protein_coding | tolerated(0.23) | benign(0.049) | TCGA-LL-A6FP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
FYN | SNV | Missense_Mutation | rs760289292 | c.721N>T | p.Arg241Cys | p.R241C | P06241 | protein_coding | tolerated(0.06) | benign(0.005) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
FYN | SNV | Missense_Mutation | c.478N>A | p.Glu160Lys | p.E160K | P06241 | protein_coding | deleterious(0) | probably_damaging(0.982) | TCGA-EK-A2R8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FYN | SNV | Missense_Mutation | novel | c.439N>A | p.Glu147Lys | p.E147K | P06241 | protein_coding | deleterious(0.02) | benign(0.179) | TCGA-IR-A3LH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
FYN | SNV | Missense_Mutation | c.1540G>A | p.Glu514Lys | p.E514K | P06241 | protein_coding | deleterious(0) | possibly_damaging(0.674) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
FYN | SNV | Missense_Mutation | c.359G>T | p.Trp120Leu | p.W120L | P06241 | protein_coding | deleterious(0) | possibly_damaging(0.735) | TCGA-UC-A7PF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
FYN | SNV | Missense_Mutation | c.1119N>T | p.Gln373His | p.Q373H | P06241 | protein_coding | deleterious(0.01) | possibly_damaging(0.821) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
FYN | SNV | Missense_Mutation | c.616N>T | p.Arg206Cys | p.R206C | P06241 | protein_coding | deleterious(0) | possibly_damaging(0.661) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD |
Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | inhibitor | CHEMBL403989 | TG100-801 | |
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | inhibitor | 385612188 | ||
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | 681640 | CHEMBL379975 | ||
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | DASATINIB | DASATINIB | ||
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | OSI-632 | OSI-632 | ||
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | ILORASERTIB | ILORASERTIB | ||
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | inhibitor | CHEMBL3545085 | XL-228 | |
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | AZAKENPAULLONE | AZAKENPAULLONE | ||
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | TAMATINIB | R-406 | ||
2534 | FYN | DRUGGABLE GENOME, CELL SURFACE, TYROSINE KINASE, KINASE, ENZYME | inhibitor | CHEMBL3545133 | JNJ-26483327 |
Page: 1 2 3 4 5 |